Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Cited by (1,000)

Items 201–300 of 1,000

1. From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview
   Carlo Gabriele Tocchetti, Christian Cadeddu Dessalvi, Daniela Di Lisi, Saveria Femminò, Rosalinda Madonna, Donato Mele, Ines Paola Monte, Giuseppina Novo, Claudia Renata Rezende Penna, Alessia Pepe et al. · 2017 · Antioxidants and Redox Signaling
2. The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
   Monica Girotra, Aaron Richard Hansen, Azeez Farooki, David J. Byun, Le Min, Ben Creelan, Margaret K. Callahan, Michael B. Atkins, Elad Sharon, Scott Joseph Antonia et al. · 2018 · JNCI Cancer Spectrum
3. Autoimmune complications of immunotherapy: pathophysiology and management
   Karmela K Chan, Anne R. Bass · 2020 · BMJ
4. Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma
   Zhao, Fei, Evans, Kathy, Xiao, Christine, DeVito, Nicholas, Theivanthiran, Balamayooran, Holtzhausen, Alisha, Siska, Peter J., Blobe, Gerard C., Hanks, Brent A. · 2018 · Cancer Immunology Research
5. Immune Checkpoint Inhibitor Toxicity
   David James Palmieri, Matteo Salvatore Carlino · 2018 · Current Oncology Reports
6. T-Cell Therapy Using Interleukin-21–Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression
   Aude G. Chapuis, Ilana M. Roberts, John A. Thompson, Kim Allyson Margolin, Shailender Bhatia, Sylvia M. Lee, Heather L. Sloan, Ivy P. Lai, Erik A. Farrar, Felecia D. Wagener et al. · 2016 · Journal of Clinical Oncology
7. CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
   Lisa Ann Gerdes, Kathrin Held, Eduardo Beltrán, Carola Berking, Jörg C. Prinz, Andreas Junker, Julia K. Tietze, Birgit Betina Ertl-Wagner, Andreas M. Straube, Tania Kümpfel et al. · 2016 · Annals of Neurology
8. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis
   Mitchell S. von Itzstein, Shaheen Khan, David E. Gerber · 2020 · Clinical Chemistry
9. Opportunistic infections in patients treated with immunotherapy for cancer
   Chrisann Kyi, Matthew David Hellmann, Jedd D. Wolchok, Paul B. Chapman, Michael A. Postow · 2014 · Journal for ImmunoTherapy of Cancer
10. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
    Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2018 · Current Cancer Drug Targets
11. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
    Xiaohui Jia, Luying Geng, Panpan Jiang, Hongxia Xu, Kejun Nan, Yu Yao, Lili Jiang, Hong Sun, Tianjie Qin, Hui Guo · 2020 · Journal of Experimental & Clinical Cancer Research
12. Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
    Jonathan M. Pitt, Marie Vétizou, Nadine Waldschmitt, Guido Kroemer, Mathias Chamaillard, Ivo Gomperts Boneca, Laurence Zitvogel · 2016 · Cancer Research
13. Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
    Laura C. Cappelli, Ami A. Shah, Clifton O. Bingham · 2016 · Rheumatic Disease Clinics of North America
14. Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
    Daphne Day, Aaron Richard Hansen · 2016 · BioDrugs
15. 64Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
    Kei Higashikawa, Katsuharu Yagi, Keiko Watanabe, Shinichiro Kamino, Masashi Ueda, Makoto Hiromura, Shuichi Enomoto · 2014 · PLoS ONE
16. ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
    Francesco Torino, Agnese Barnabei, Rosa Maria Paragliola, Paolo Marchetti, Roberto Salvatori, Salvatore Maria Corsello · 2013 · European Journal of Endocrinology
17. Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment
    Mizuki Nishino, Sree Harsha Tirumani, Nikhil H. Ramaiya, Frank Stephen Hodi · 2015 · European Journal of Radiology
18. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management
    Romualdo Barroso‐Sousa, Patrick Alexander Ott, Frank Stephen Hodi, Ursula B. Kaiser, Sara M. Tolaney, Le Min · 2018 · Cancer
19. Immune checkpoint inhibitor-related hepatotoxicity: A review
    Devika Remash, David Stephen Prince, Catriona A. McKenzie, Simone Irene Strasser, Steven Kao, Ken Liu · 2021 · World Journal of Gastroenterology
20. Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis
    Lei Zhang, Han Zheng, Shitao Jiang, Yao-Ge Liu, Ting Zhang, Junwei Zhang, Xin Lü, Haitao Zhao, Xinting Sang, Yiyao Xu · 2024 · International Journal of Surgery
21. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
    Naoka Murakami, Thiago J. Borges, Michifumi Yamashita, Leonardo V. Riella · 2016 · Clinical Kidney Journal
22. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review
    Jonathan G. Stine, James H. Lewis · 2015 · Expert Review of Gastroenterology & Hepatology
23. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
    Johnson, Daniel, Patel, Anisha B., Uemura, Marc I., Trinh, Van A., Jackson, Natalie, Zobniw, Chrystia M., Tetzlaff, Michael T., Hwu, Patrick, Curry, Jonathan L., Diab, Adi · 2019 · Cancer Immunology Research
24. Cutaneous manifestations associated with immune checkpoint inhibitors
    Tomoya Watanabe, Yukie Yamaguchi · 2023 · Frontiers in Immunology
25. Myositis as an adverse event of immune checkpoint blockade for cancer therapy
    Mohsin Shah, Jean H. Tayar, Noha Abdel‐Wahab, Maria Eugenia Suarez-Almazor · 2018 · Seminars in Arthritis and Rheumatism
26. Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
    Douglas Buckner Johnson, Vita Saranga‐Perry, Patrick Lavin, William Bryan Burnette, Stephen W. Clark, David Uskavitch, Deborah E. Wallace, Mark Andrew Dickson, Ragini Reiney Kudchadkar, Jeffrey Alan Sosman · 2014 · Journal of Clinical Oncology
27. Toxicity management of immunotherapy for patients with metastatic melanoma
    Helena Linardou, Helen J Gogas · 2016 · Annals of Translational Medicine
28. Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
    Igor Barjaktarević, Nida Qadir, Anu Suri, Jean T. Santamauro, Diane E. Stover · 2013 · CHEST Journal
29. Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges
    Yael Diesendruck, Itai Benhar · 2017 · Drug Resistance Updates
30. Thyroid disorders induced by checkpoint inhibitors
    Silvia Martina Ferrari, Poupak Fallahi, Fabio Galetta, Emanuele Citi, Salvatore Benvenga, Alessandro Antonelli · 2018 · Reviews in Endocrine and Metabolic Disorders
31. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis
    Shannon Wongvibulsin, Vartan Pahalyants, Mark Kalinich, William Murphy, Kun‐Hsing Yu, Feicheng Wang, Steven T. Chen, Kerry Lynn Reynolds, Shawn G. Kwatra, Yevgeniy R. Semenov · 2021 · Journal of the American Academy of Dermatology
32. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma
    Brandon M. Huffman, Lisa A. Kottschade, Patrick S. Kamath, Svetomir N. Markovic · 2017 · American Journal of Clinical Oncology
33. Toxicities Associated With PD-1/PD-L1 Blockade
    Daniel Y. Wang, Douglas Buckner Johnson, Elizabeth J. Davis · 2018 · The Cancer Journal
34. Autoimmune endocrine dysfunctions associated with cancer immunotherapies
    Ferrari, Silvia Martina, Fallahi, Poupak, Elia, Giusy, Ragusa, Francesca, Ruffilli, Ilaria, Patrizio, Armando, Galdiero, Maria Rosaria, Baldini, Enke, Ulisse, Salvatore, Marone, Gianni et al. · 2019 · International Journal of Molecular Sciences
35. Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti–PD-1 Therapy
    Richard Wayne Joseph, Mark Aaron Cappel, Brent Goedjen, Matthew C. Gordon, Brandon Kirsch, Cheryl Gilstrap, Sanjay Prakash Bagaria, Anokhi Jambusaria‐Pahlajani · 2014 · Cancer Immunology Research
36. Aptamer-Based Logic Computing Reaction on Living Cells to Enable Non-Antibody Immune Checkpoint Blockade Therapy
    Yu Pu Yang, Jun Xu, Yang Sun, Liuting Mo, Bo Liu, Xiaoshu Pan, Zhuang Liu, Weihong Tan · 2021 · Journal of the American Chemical Society
37. Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
    Kent C. Shih, Hendrik‐Tobias Arkenau, Jeffrey R. Infante · 2014 · Drugs
38. Ipilimumab in the treatment of metastatic melanoma: management of adverse events
    Giuseppina Della Vittoria Scarpati, Celeste Fusciello, Francesco Perri, Francesco Sabbatino, Chiara Carlomagno, Stefano Pepe, Soldano Ferrone · 2014 · OncoTargets and Therapy
39. The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond
    Ziqiang Zhu, Wei Liu, Vladimir K. Gotlieb · 2015 · Critical Reviews in Oncology/Hematology
40. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings
    Gary X. Wang, Vikram Kurra, Justin F. Gainor, Ryan Joseph Sullivan, Keith T. Flaherty, Susanna I. Lee, Florian Johannes Fintelmann · 2017 · Radiographics
41. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management
    Shilpa Grover, Osama E. Rahma, Nikroo Hashemi, Ramona M. Lim · 2018 · American Society of Clinical Oncology Educational Book
42. Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study
    Jair Bar, Gal Markel, Teodor Gottfried, Ruth Percik, Raya Leibowitz‐Amit, Raanan Berger, Talia Golan, Sameh Daher, Alisa Taliansky, Elizabeth Dudnik et al. · 2019 · European Journal of Cancer
43. European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement
    Zoé Apalla, Vasiliki A. Nikolaou, Davide Fattore, Gabriella Fabbrocini, Azael Freites‐Martínez, Pietro Sollena, Mario E. Lacouture, Lukas Kraehenbuehl, Alexander Stratigos, Ketty Peris et al. · 2021 · Journal of the European Academy of Dermatology and Venereology
44. Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
    Samaan, Mark A., Pavlidis, Polychronis, Papa, Sophie, Powell, Nick, Irving, Peter M. · 2018 · Nature Reviews Gastroenterology & Hepatology
45. Targeting Oncogenic Drivers and the Immune System in Melanoma
    Grant A. McArthur, Antoni Ribas · 2012 · Journal of Clinical Oncology
46. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
    Sophie C. Postel-Vinay, Sandrine Aspeslagh, Émilie Lanoy, Caroline Robert, Jean‐Charles Soria, Aurélien Marabelle · 2015 · Annals of Oncology
47. Immune‐Related Adverse Events From Immune Checkpoint Inhibitors
    Kristen Ashley Marrone, W Ying, Jarushka Naidoo · 2016 · Clinical Pharmacology & Therapeutics
48. Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
    Christophoros Astaras, Rita De Micheli, Bianca Gautron Moura, Thomas Hundsberger, Andreas Felix Hottinger · 2018 · Current Neurology and Neuroscience Reports
49. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
    Caroline Robert, Wen‐Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber, ADIL I. DAUD, Frank Stephen Hodi, Jedd D. Wolchok, Tara C. Mitchell, Peter Hersey et al. · 2020 · European Journal of Cancer
50. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
    Jing Lü, Linda Lee-Gabel, Michelle C Nadeau, Thomas M. Ferencz, Scott A. Soefje · 2014 · Journal of Oncology Pharmacy Practice
51. New insight in endocrine-related adverse events associated to immune checkpoint blockade
    Giusy Elia, Silvia Martina Ferrari, Maria Rosaria Galdiero, Francesca Ragusa, Sabrina Rosaria Paparo, Ilaria Ruffilli, Gilda Varricchi, Poupak Fallahi, Alessandro Antonelli · 2019 · Best Practice & Research Clinical Endocrinology & Metabolism
52. Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
    Isobel Okoye, Michael Houghton, D. Lorne Tyrrell, Khaled Barakat, Shokrollah Elahi · 2017 · Frontiers in Immunology
53. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
    Silvana Morello, Mariaelena Capone, Claudia Sorrentino, Diana Giannarelli, Gabriele Madonna, Domenico Mallardo, Antonio Maria Grimaldi, Aldo Pinto, Paolo A. Ascierto · 2017 · Journal of Translational Medicine
54. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
    Johnson, Douglas B., Friedman, Debra L., Berry, Elizabeth, Decker, Ilka, Ye, Fei, Zhao, Shilin, Morgans, Alicia K., Puzanov, Igor, Sosman, Jeffrey A., Lovly, Christine M. · 2015 · Cancer Immunology Research
55. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy
    David Mark Francis, Susan Napier Thomas · 2017 · Advanced Drug Delivery Reviews
56. Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
    Aaron Elliott Lisberg, D. Andrew Tucker, Jonathan Wade Goldman, Brian Wolf, James Carroll, Ariana Hardy, Karolyn K. Morris, Paulina Linares, Carlos R. Adame, Marshall L. Spiegel et al. · 2018 · Cancer Immunology Research
57. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
    Yuwen Zhou, Yajuan Zhu, Man‐Ni Wang, Yao Xie, Chao-Yue Chen, Tao Zhang, Fan Xia, Zhenyu Ding, Jiyan Liu · 2019 · Frontiers in Pharmacology
58. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
    Vanna Chiarion‐Sileni, Jacopo Pigozzo, Paolo A. Ascierto, Antonio Maria Grimaldi, Michele Maio, Lorenza Di Guardo, Paolo Marchetti, Francesco De Rosa, Carmen M. A. Nuzzo, Alessandro Testori et al. · 2014 · Journal of Experimental & Clinical Cancer Research
59. Renal complications of immune checkpoint blockade
    Naoka Murakami, Shveta S. Motwani, Leonardo V. Riella · 2016 · Current Problems in Cancer
60. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab
    Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka, Takeru Funakoshi, Taku Fujimura, Yuki Yamamoto, Hiroo Hata, Masahiko Gosho, Ryota Tanaka, Kei Yamaguchi et al. · 2017 · Journal of Dermatological Science
61. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin
    Jain, Varun, Mohebtash, Mahsa, Rodrigo, Maria E., Ruiz, George, Atkins, Michael B., Barac, Ana · 2018 · Journal of Immunotherapy
62. The development of immunotherapy in older adults: New treatments, new toxicities?
    Carole Hélissey, Cécile Vicier, Stéphane Champiat · 2016 · Journal of Geriatric Oncology
63. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells
    Themis Alissafi, Aikaterini Hatzioannou, A.I. Legaki, Athina Varveri, Panayotis Verginis · 2019 · Journal of Autoimmunity
64. Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020
    Shruti Gupta, Frank B. Cortazar, Leonardo V. Riella, David E. Leaf · 2020 · Kidney360
65. Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
    Stéphane Champiat, Ecaterina E. Ileana, Giuseppe Giaccone, Benjamin Besse, Giannis Mountzios, Alexander M.M. Eggermont, Jean‐Charles Soria · 2014 · Journal of Thoracic Oncology
66. Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
    Hans‐Joachim Schmoll, Burghardt Wittig, Dirk Arnold, Jorge Riera‐Knorrenschild, Dieter Nitsche, Hendrik Kroening, Frank Mayer, Johannes Andel, Reinhard Ziebermayr, Werner Scheithauer · 2014 · Journal of Cancer Research and Clinical Oncology
67. Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer
    Jing Liu, Stephen J. Blake, Heidi Harjunpää, Kirsten A. Fairfax, Michelle C.R. Yong, Stacey M. Allen, Holbrook E K Kohrt, Kazuyoshi Takeda, Mark John Smyth, Michele W.L. Teng · 2016 · Cancer Research
68. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system
    Yingying Hu, Jian Gong, Lifu Zhang, Xiaolin Li, Xina Li, Bin Zhao, Xin Hai · 2020 · International Immunopharmacology
69. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
    Anna Śledzińska, Laurie Menger, Katharina F. Bergerhoff, Karl S. Peggs, Sergio A. Quezada · 2015 · Molecular Oncology
70. New Strategies in Bladder Cancer: A Second Coming for Immunotherapy
    Ali Ghasemzadeh, Trinity Jude Bivalacqua, Noah M. Hahn, Charles G. Drake · 2015 · Clinical Cancer Research
71. Immunotherapy for advanced hepatocellular carcinoma, where are we?
    Zhang Li, Jia Ding, Huiyan Li, Zhonghua Wang, Jian Wu · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
72. Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma
    Jasna Aleksova, Peter K. H. Lau, Georgia Soldatos, Grant A. McArthur · 2016 · BMJ Case Reports
73. Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response
    Melanie H. Smith, Anne R. Bass · 2017 · Arthritis Care & Research
74. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies
    Joseph J. Jennings, Rohan H. Mandaliya, Ahmad Nakshabandi, James H. Lewis · 2019 · Expert Opinion on Drug Metabolism & Toxicology
75. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
    On behalf of the Italian Melanoma Intergroup (IMI), Maria Pia Pistillo, Vincenzo Fontana, Anna Morabito, Béatrice Dozin, Stefania Laurent, Roberta Carosio, Barbara Banelli, Francesca Ferrero, Laura Spano et al. · 2018 · Cancer Immunology Immunotherapy
76. Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?
    Mussarat Nazia Rahim, Rodrigo Liberal, Rosa Miquel, Nigel David Heaton, Michael A. Heneghan · 2019 · Liver Transplantation
77. Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced Melanoma
    Anthony J. Olszanski · 2014 · Journal of Managed Care Pharmacy
78. Ipilimumab in patients with melanoma and autoimmune disease
    Chrisann Kyi, Richard D. Carvajal, Jedd D. Wolchok, Michael A. Postow · 2014 · Journal for ImmunoTherapy of Cancer
79. The diagnosis and management of idiosyncratic drug‐induced liver injury
    Ammar Hassan, Robert J. Fontana · 2018 · Liver International
80. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
    Hamzah Abu‐Sbeih, Faisal S. Ali, Wei Qiao, Yang Lü, Sapna Pradyuman Patel, Adi K. Diab, Yinghong Wang · 2019 · Cancer Immunology Immunotherapy
81. Immune‐related adverse reactions in the hepatobiliary system: second‐generation check‐point inhibitors highlight diverse histological changes
    Yoh Zen, Yen‐Ying Chen, Yung‐Ming Jeng, Hung‐Wen Tsai, Matthew M. Yeh · 2019 · Histopathology
82. Neurological sequelae of cancer immunotherapies and targeted therapies
    Wick, Wolfgang, Hertenstein, Anne, Platten, Michael · 2016 · The Lancet Oncology
83. Immune reconstitution inflammatory syndrome in non‐ HIV immunosuppressed patients
    Hirohiko Sueki, Yoshiko Mizukawa, Yumi Aoyama · 2017 · The Journal of Dermatology
84. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
    Bruce C. Tiu, Leyre Zubiri, James Iheke, Vartan Pahalyants, Nicholas Theodosakis, Pearl Ugwu‐Dike, Jayhyun Seo, Kimberly Tang, Meghan E. Sise, Ryan Joseph Sullivan et al. · 2022 · Journal for ImmunoTherapy of Cancer
85. ImmTACs for targeted cancer therapy: Why, what, how, and which
    Joanne Oates, Namir J. Hassan, Bent K. Jakobsen · 2015 · Molecular Immunology
86. Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis
    Katharina Lankes, Gheorghe Hundorfean, Thomas Harrer, Ansgar J. Pommer, Abbas Agaimy, Irena Angelovska, Azadeh Tajmir-Riahi, J. Göhl, Gerold Schuler, Markus Friedrich Neurath et al. · 2016 · OncoImmunology
87. Histopathological and immunophenotypic features of ipilimumab‐associated colitis compared to ulcerative colitis
    Brittany L. Adler, Maryam Kherad Pezhouh, Allison Kim, L. Luan, Qingfeng Zhu, Faiz Gani, Mark M. Yarchoan, J. Chen, Lysandra Voltaggio, Alyssa M. Parian et al. · 2018 · Journal of Internal Medicine
88. Risk of Gastrointestinal Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis
    Omar Mohammed Abdel-Rahman, Hesham M. Elhalawani, Mona Fouad · 2015 · Immunotherapy
89. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development
    Arie Regev, Mark Avigan, Alexandre Kiazand, John Moore Vierling, James H. Lewis, Stephanie O. Omokaro, Adrian M. Di Bisceglie, Robert J. Fontana, Herbert L. Bonkovsky, James W. Freston et al. · 2020 · Journal of Autoimmunity
90. Immune Checkpoint Inhibitors Side Effects and Management
    Hampig Raphaël Kourié, Jean A. Klastersky · 2016 · Immunotherapy
91. Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
    Jarushka Naidoo, Laura C. Cappelli, Patrick M. Forde, Kristen Ashley Marrone, Evan J. Lipson, Hans J. Hammers, William Howard Sharfman, Dung Thi Le, Alan N. Baer, Ami A. Shah et al. · 2017 · The Oncologist
92. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer
    Cristina Gutiérrez, Colleen A. McEvoy, Laveena Munshi, Robert Scott Stephens, Michael E. Detsky, Joseph L. Nates, Stephen M. Pastores · 2019 · Critical Care Medicine
93. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis
    Parul Tandon, Samuel Bourassa‐Blanchette, Kirles Bishay, Simon Parlow, Scott Andrew Laurie, Jeffrey D. McCurdy · 2018 · Journal of Immunotherapy
94. Immune checkpoint inhibitors and the development of granulomatous reactions
    Christine M. Cornejo, Paul Haun, Joseph C. English, Misha A. Rosenbach · 2018 · Journal of the American Academy of Dermatology
95. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
    Cousin, Sophie, Italiano, Antoine · 2016 · Clinical Cancer Research
96. Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma
    Shannon K. Quirk, Anna K. Shure, Devendra K. Agrawal · 2015 · Translational research
97. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis
    Cindy Franklin, Isabelle Rooms, Melanie Fiedler, Henning Reis, Laura Milsch, Saskia Herz, Elisabeth Livingstone, Lisa Zimmer, Kurt Werner Schmid, Ulf Dittmer et al. · 2017 · European Journal of Cancer
98. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition
    Arlene Odelia Siefker-Radtke, Brendan D. Curti · 2017 · Nature Reviews Urology
99. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies
    Jay Alan Fishman, John I Hogan, Marcela Valderrama Maus · 2018 · Clinical Infectious Diseases
100. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis
     Julia Dai, Viswanath Reddy Belum, Shenhong Wu, Vincent Sibaud, Mario E. Lacouture · 2017 · Journal of the American Academy of Dermatology